Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Patient preference for radial versus femoral vascular access for elective coronary procedures: The PREVAS study.

Kok MM, Weernink MGM, von Birgelen C, Fens A, van der Heijden LC, van Til JA.

Catheter Cardiovasc Interv. 2017 May 4. doi: 10.1002/ccd.27039. [Epub ahead of print]

PMID:
28470994
2.

Three-Year Clinical Outcome of Patients with Coronary Disease and Increased Event Risk Treated with Newer-Generation Drug-Eluting Stents: From the Randomized DUTCH PEERS Trial.

van der Heijden LC, Kok MM, Löwik MM, Danse PW, Jessurun GAJ, Hartmann M, Stoel MG, van Houwelingen KG, Hautvast RWM, Linssen GC, Doggen CJM, von Birgelen C.

Cardiology. 2017 Apr 27;137(4):207-217. doi: 10.1159/000464320. [Epub ahead of print]

PMID:
28445871
3.

Giant cell tumour of bone in the denosumab era.

van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.

Eur J Cancer. 2017 May;77:75-83. doi: 10.1016/j.ejca.2017.02.021. Epub 2017 Mar 30. Review.

PMID:
28365529
4.

Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial.

von Birgelen C, van der Heijden LC, Basalus MW, Kok MM, Sen H, Louwerenburg HW, van Houwelingen KG, Stoel MG, de Man FH, Linssen GC, Tandjung K, Doggen CJ, van der Palen J, Löwik MM.

JAMA Cardiol. 2017 Mar 1;2(3):268-276. doi: 10.1001/jamacardio.2016.5190.

PMID:
28114618
5.

Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial.

van der Heijden LC, Kok MM, Löwik MM, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Hartmann M, Linssen GC, Doggen CJM, von Birgelen C.

EuroIntervention. 2017 Apr 20;12(17):2128-2131. doi: 10.4244/EIJ-D-16-00571.

6.

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.

von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, Gin RMTJ, Somi S, van Houwelingen KG, Stoel MG, de Man FHAF, Louwerenburg JHW, Hartmann M, Zocca P, Linssen GCM, van der Palen J, Doggen CJM, Löwik MM.

Lancet. 2016 Nov 26;388(10060):2607-2617. doi: 10.1016/S0140-6736(16)31920-1. Epub 2016 Oct 30.

PMID:
27806902
7.

Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial.

van Houwelingen KG, van der Heijden LC, Lam MK, Kok MM, Löwik MM, Louwerenburg JW, Linssen GC, IJzerman MJ, Doggen CJ, von Birgelen C.

Heart Vessels. 2016 Nov;31(11):1731-1739. Epub 2016 Jan 8.

8.

Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study.

Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JH, Holm NR, Wijns W; FAVOR Pilot Trial Study Group..

JACC Cardiovasc Interv. 2016 Oct 10;9(19):2024-2035. doi: 10.1016/j.jcin.2016.07.013.

PMID:
27712739
9.

Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERS.

Huisman J, van der Heijden LC, Kok MM, Louwerenburg JH, Danse PW, Jessurun GA, de Man FH, Löwik MM, Linssen GC, IJzerman MJ, Doggen CJ, von Birgelen C.

J Cardiol. 2017 Apr;69(4):660-665. doi: 10.1016/j.jjcc.2016.06.010. Epub 2016 Jul 28.

PMID:
27476343
10.

Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.

Mukete BN, van der Heijden LC, Tandjung K, Baydoun H, Yadav K, Saleh QA, Doggen CJ, Abi Rafeh N, Le Jemtel TH, von Birgelen C.

Int J Cardiol. 2016 Oct 15;221:1087-94. doi: 10.1016/j.ijcard.2016.07.101. Epub 2016 Jul 9. Review.

11.

Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial.

van der Heijden LC, Kok MM, Danse PW, Schramm AR, Hartmann M, Löwik MM, Linssen GC, Stoel MG, Doggen CJ, von Birgelen C.

Am Heart J. 2016 Jun;176:28-35. doi: 10.1016/j.ahj.2016.02.020. Epub 2016 Mar 17.

PMID:
27264217
12.

Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II).

Huisman J, van der Heijden LC, Kok MM, Danse PW, Jessurun GA, Stoel MG, van Houwelingen KG, Löwik MM, Hautvast RW, IJzerman MJ, Doggen CJ, von Birgelen C.

Am Heart J. 2016 May;175:121-9. doi: 10.1016/j.ahj.2016.02.012. Epub 2016 Feb 26.

13.

Pigmented villonodular synovitis: a crowdsourcing study of two hundred and seventy two patients.

van der Heijden L, Piner SR, van de Sande MA.

Int Orthop. 2016 Dec;40(12):2459-2468. Epub 2016 May 12.

PMID:
27169531
14.

Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials.

Kok MM, van der Heijden LC, Sen H, Danse PW, Löwik MM, Anthonio RL, Louwerenburg JH, de Man FH, Linssen GC, IJzerman MJ, Doggen CJ, Maas AH, Mehran R, von Birgelen C.

JACC Cardiovasc Interv. 2016 Mar 28;9(6):553-61. doi: 10.1016/j.jcin.2015.10.043. Epub 2016 Mar 2.

15.

Reply: Post-Percutaneous Coronary Intervention Angina: A New Performance Measure?

von Birgelen C, van der Heijden LC, Sen H, Löwik MM.

JACC Cardiovasc Interv. 2015 Oct;8(12):1640-1. doi: 10.1016/j.jcin.2015.08.006. No abstract available.

16.

Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.

van der Heijden LC, Kok MM, Lam MK, Danse PW, Schramm AR, Jessurun GA, Tjon Joe Gin RM, van Houwelingen KG, Hautvast RW, Linssen GC, Sen H, Löwik MM, IJzerman MJ, Doggen CJ, von Birgelen C.

Clin Res Cardiol. 2016 Mar;105(3):206-15. doi: 10.1007/s00392-015-0907-3. Epub 2015 Sep 2.

17.

Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).

Sen H, Lam MK, Löwik MM, Danse PW, Jessurun GA, van Houwelingen KG, Anthonio RL, Tjon Joe Gin RM, Hautvast RW, Louwerenburg JH, de Man FH, Stoel MG, van der Heijden LC, Linssen GC, IJzerman MJ, Tandjung K, Doggen CJ, von Birgelen C.

JACC Cardiovasc Interv. 2015 Jun;8(7):889-99. doi: 10.1016/j.jcin.2015.01.033. Epub 2015 May 20.

18.

Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.

van der Heijden L, van de Sande MA, Hogendoorn PC, Gelderblom H, Dijkstra PD.

Acta Orthop. 2015 Jun;86(3):393-5. doi: 10.3109/17453674.2014.1002345. Epub 2015 Feb 14. No abstract available.

19.

Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial.

Lam MK, Sen H, van Houwelingen KG, Löwik MM, van der Heijden LC, Kok MM, de Man FH, Linssen GC, Tandjung K, Doggen CJ, von Birgelen C.

Am Heart J. 2015 Jan;169(1):69-77. doi: 10.1016/j.ahj.2014.10.011. Epub 2014 Oct 25.

PMID:
25497250
20.

Transverse myelitis in measles.

van der Heijden LB, Janse AJ.

Pediatr Neurol. 2015 Jan;52(1):132. doi: 10.1016/j.pediatrneurol.2014.09.018. Epub 2014 Oct 5. No abstract available.

PMID:
25451019

Supplemental Content

Loading ...
Support Center